MAPK3 and melanoma: In addition, EGFR was correlated with resistance to BRAF inhibitors [102,103] by contributing to activity of ERK1/2 and AKT through a physical interaction with urokinase type plasminogen activator receptor (uPAR) in melanoma cells [114,115].